

**Supplementary Table S5. Specific therapies patients received before CAR-T cell therapy.**

Patient	Lines	Treatment	
1	4	<b>PAD</b> <b>RCD</b> <b>D-RICD</b> <b>D-IMP</b>	<b>PAD:</b> Bortezomib, doxorubicin and dexamethasone <b>RCD:</b> Lenalidomide, cyclophosphamide and dexamethasone
2	6	<b>PAD</b> <b>RCD</b> <b>IRD</b> <b>DECP</b> <b>DRD</b> <b>Dara+ P+DEAP</b>	<b>D-RICD:</b> Daratumumab, lenalidomide, ixazomib, cyclophosphamide and dexamethasone <b>D-IMP:</b> Daratumumab, ixazomib, melphalan and prednisone <b>IRD:</b> Ixazomib, lenalidomide and dexamethasone <b>DECP:</b> Dexamethasone, etoposide, cyclophosphamide and cisplatin <b>DRD:</b> Daratumumab, lenalidomide and dexamethasone
3	7	<b>PAD</b> <b>PCD</b> <b>VRD</b> <b>RMP</b> <b>IRD</b> <b>Dara+DECP</b> <b>P+IMP</b>	<b>Dara:</b> Daratumumab <b>P:</b> Pomalidomide <b>DEAP:</b> Dexamethasone, etoposide, doxorubicin and cisplatin
4	7	<b>PAD</b> <b>VRAD</b> <b>Dara+DECP+ Lenalidomide</b> <b>IPD+RTX</b> <b>doxorubicin +VEN</b> <b>Bendamustine</b> <b>VPD+PACE</b>	<b>VRD:</b> Bortezomib, lenalidomide and dexamethasone <b>RMP:</b> Lenalidomide, melphalan and prednisone <b>IRD:</b> Ixazomib, lenalidomide and dexamethasone <b>VRAD:</b> Bortezomib, lenalidomide, doxorubicin and dexamethasone <b>Dara:</b> Daratumumab
5	7	<b>RD</b> <b>ICD</b> <b>PAD</b> <b>DPd</b> <b>VPD+PACE</b> <b>ASCT</b> <b>Selinexor</b>	<b>IPD:</b> Ixazomib, pomalidomide and dexamethasone <b>RTX:</b> Radiation therapy <b>VEN:</b> Venetoclax <b>Rd:</b> Lenalidomide and dexamethasone <b>ICD:</b> Ixazomib, cyclophosphamide and dexamethasone
6	3	<b>PCD</b> <b>VRD</b> <b>ASCT</b>	<b>PACE:</b> Cisplatin, Adriamycin, cyclophosphamide and etoposide
7	6	<b>PAD</b> <b>VRD</b> <b>ASCT</b> <b>ICD</b> <b>IMP</b> <b>D-IMP</b>	<b>DPd:</b> Daratumumab, pomalidomide, and dexamethasone <b>ASCT:</b> Autologous stem cell transplantation <b>Pom-Dex:</b> Pomalidomide and dexamethasone

